TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00428142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3mg/m2 days 1 \& 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40mg/m2 days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4mg/m2 day 1 (dose capped at 2mg)
Study: NCT01328951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-Line Chemotherapy
Description: Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
Study: NCT03972787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive social robot
Description: ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
Study: NCT02162836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
Study: NCT03483142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: ( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
Study: NCT03331055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Description: percutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical nerve stimulation
Study: NCT01197521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily/150 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, fostamatinib
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
Study: NCT03705637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: * Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation.
Study: NCT00562952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan, Bisoprolol
Description: Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention
Study: NCT00711620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymosin alpha 1
Description: 1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Study: NCT03085524

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function testing
Description: The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function testing
Description: The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization

Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular ultrasonography
Description: The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular ultrasonography
Description: The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
Study: NCT03200366

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored DVD
Description: A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored DVD
Description: A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
Study: NCT04564742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg tablets given once daily, per oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
Study: NCT01396174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prosocial online support group
Description: Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Online Support Group
Description: Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
Study: NCT02081040

Intervention type: OTHER
Intervention: Not applicable (observational study with no active intervention)
Study: NCT01785459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: 10 mg Intravenous injection of Prochlorperazine
Study: NCT00501371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS
Description: soft-gel capsule, 15 mg/cap., Qd, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soft-gel capsule, Qd, 12 weeks
Study: NCT04278209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 1
Description: Participant will receive Breakfast 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 1
Description: Participant will receive Breakfast 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 1
Description: Participant will receive Breakfast 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 1
Description: Participant will receive Breakfast 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 2
Description: Participant will receive Breakfast 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 2
Description: Participant will receive Breakfast 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 2
Description: Participant will receive Breakfast 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast 2
Description: Participant will receive Breakfast 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participant will receive water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participant will receive water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participant will receive water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participant will receive water
Study: NCT03295877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7171009
Description: Patients will receive RO7171009 via ITV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7171009
Description: Patients will receive RO7171009 via ITV injection.
Study: NCT01568398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study: NCT02692365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance + hemodynamic + infusion of gadolinium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance + hemodynamic + infusion of gadolinium
Study: NCT01390272

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booster/ low resource
Description: A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster/ low resource
Description: A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium/Level 1 resource intensity
Description: Monthly tailored RN delivered calls + home BP monitoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High/Level 2 resource intensity
Description: Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
Study: NCT00596661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriMaxx Coronary Stent placement
Description: Angioplasty with coronary artery stent placement
Study: NCT01072305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Description: Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IPC - placebo
Description: ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
Study: NCT01651351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1-proteinase inhibitor
Description: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1-proteinase inhibitor
Description: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo: Human albumin 2.5%
Description: Intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo: Human albumin 2.5%
Description: Intravenous administration
Study: NCT04254068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-based prevention
Description: Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
Study: NCT00362349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgNextGen 10%
Description: Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days
Study: NCT00679510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: tablet 10 mgs once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03944226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
Study: NCT02403336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training health professionals
Description: Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral group intervention
Description: Intervention on patients (educational workshop).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical practice
Description: Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
Study: NCT03890783

Intervention type: OTHER
Intervention: Evaluation of phonation quality
Description: Evaluation of phonation quality by :~* Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~* Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia

Intervention type: OTHER
Intervention: Evaluation of swallowing quality
Description: Evaluation of swallowing quality by:~* Self-evaluation: completion of the Deglutition Handicap Index questionnaire~* Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation

Intervention type: OTHER
Intervention: global quality of life questionnaire
Description: Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H\&N35 questionnaires
Study: NCT03525717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routine Dinner
Description: Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine Dinner
Description: Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Late dinner
Description: Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Late dinner
Description: Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
Study: NCT00708149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole OD
Description: arm 1: lansprazole 30 mg qd from NG route or orally for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: takepron placebo
Study: NCT01786603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline 2mg once a day for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
Study: NCT04071743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore Sapphire
Description: non-invasive vagus nerve stimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham gammaCore Sapphire
Description: sham gammaCore Sapphire
Study: NCT03173729

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor Point of Care Device
Description: This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor Point of Care Device
Description: This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor Point of Care Device
Description: This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor Point of Care Device
Description: This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
Study: NCT03096951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
Study: NCT02997735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Delivered Treatment
Description: The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quitline Delivered Treatment
Description: The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
Study: NCT03025230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling and electric stimulation
Description: Dry needling technique and the application of electric stimulation of levator scapulae PG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Treatment of PG with a filiform needle in levator scapulae muscle